About The Study: Among patients with early or locally advanced triple-negative breast cancer, the addition of camrelizumab, an anti–PD-1 antibody, to neoadjuvant chemotherapy significantly improved pathological complete response.
Corresponding Authors: To contact the corresponding authors, email Zhi-Ming Shao, MD ( zhiminshao@fudan.edu.cn ) and Lei Fan, MD ( teddyfl@163.com ).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.23560)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the San Antonio Breast Cancer Symposium.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.23560?guestAccessKey=1f9e55e6-3a16-43df-9459-4a0040abc9c0&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=121324
JAMA